Biohaven Receives $80,000,000 New Round

  • Feed Type
  • Date
    11/2/2016
  • Company Name
    Biohaven
  • Mailing Address
    234 Church Street New Haven, CT 06510 USA
  • Company Description
    Biohaven is a privately-held biopharmaceutical company with particular expertise in late stage clinical development and has portfolio of multiple late stage drug assets. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC, Massachusetts General Hospital and two undisclosed pharmaceutical companies.
  • Website
    http://www.biohavenpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $80,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from this financing will be used to advance the company’s late stage clinical programs in orphan neurologic indications and other trials in areas of large unmet medical needs. Biohaven plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.
  • M&A Terms
  • Venture Investor
    Venrock
  • Venture Investor
    RA Capital
  • Venture Investor
    Vivo Capital
  • Venture Investor
    Aisling Capital
  • Venture Investor
    Rock Springs Capital
  • Venture Investor
    Investor
  • Venture Investor
    Knollwood Investment Advisory
  • Venture Investor
    Osage Partners
  • Venture Investor
    Aperture Venture Partners
  • Venture Investor
    Connecticut Innovations
  • Venture Investor
    Investor
  • Venture Investor
    Undisclosed

Trending on Xconomy